

Fresenius Kabi Canada Ltd.

165 Galaxy Blvd, Suite 100 Toronto, Ontario Canada M9W 0C8 T: 905.770.3711

F: 844.513.1522 W: fresenius-kabi.ca

June 2, 2025

## **Product Allocations Updates**

Dear Valued Customer,

Fresenius Kabi Canada would like to advise of allocation updates effective **June 1, 2025**. Contract customers will be allocated **volumes based on historical demand.** Please see below for details.

| DIN      | Fresenius<br>Kabi Product<br>Code | MDP<br>Product<br>Code | McKesson<br>Product<br>Code | Product Description   | Allocation                               |  |
|----------|-----------------------------------|------------------------|-----------------------------|---|--|--|
| 02267659 | C605102                           | 937071                 | 192880                      | Adenosine Injection, USP<br>3 mg/mL, 2 mL Vial                  | 100% Allocation                          |  |
| 02242905 | C410201                           | 922560                 | 23017                       | Midazolam Injection, USP<br>5 mg/mL, 1 mL Vial                  | 100% Allocation                          |  |
| 02439379 | ABH3110                           | 974870                 | 124836                      | Ropivacaine Hydrochloride Injection,<br>USP 2 mg/mL, 100 mL Bag | 125% Allocation<br>(increased from 100%) |  |

We regret to advise that allocations for our **Sodium Chloride Injection**, **USP 4 mmol/mL**, **30 mL Vial** will be reduced. Contract customers will be allocated **75% of historical monthly demand**.

| DIN      | Fresenius<br>Kabi Product<br>Code | MDP<br>Product<br>Code | McKesson<br>Product<br>Code | Product Description                                     | Allocation  |
|----------|-----------------------------------|------------------------|-----------------------------|---|---|
| 02139510 | C918930                           | 975916                 | 158460                      | Sodium Chloride Injection,<br>USP 4 mmol/mL, 30 mL Vial | 75% Allocation<br>(reduced from 100%)   |
|          |                                   |                        |                             |   | Product will be off allocation & available without restrictions effective July 2025 |

We recognize the difficulties and inconvenience that you may encounter as a result of these allocations, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact your sales representative.

Sincerely,

Joseph Le

Associate Director, IV Drugs joseph.le@fresenius-kabi.com

